Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in patients with previously treated immune thrombocytopenia.
Medscape Medical News

source https://www.medscape.com/viewarticle/rilzabrutinib-shines-phase-3-trial-tough-treat-immune-2024a1000mlv?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?